Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery

NCT ID: NCT07027267

Last Updated: 2025-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-05

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study of a bioabsorbable implant to separate the middle turbinate from the lateral nasal wall associated with nasal/sinus surgery

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate the safety and effectiveness of the Spirair implant as a primary treatment to achieve medialization of the middle turbinate after functional endoscopic sinus surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinus Endoscopic Surgery Turbinate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open-label

Treatment with the Spirair device as a treatment for medialization of the middle turbinates

Group Type EXPERIMENTAL

Implantation of Spirair device into the middle turbinates

Intervention Type DEVICE

The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.

TurbAlign

Intervention Type DEVICE

The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation of Spirair device into the middle turbinates

The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery.

Intervention Type DEVICE

TurbAlign

The Spirair implant is designed to separate the middle turbinate from the lateral nasal wall during the healing phase associated with nasal/sinus surgery

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TurbAlign

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 to ≤ 70 years of age at time of consent
* Subject scheduled to undergo bilateral endoscopic sinus surgery
* Able to speak, read and understand English
* Willing and able to provide informed consent and comply with the study protocol

Exclusion Criteria

* History of removal of one or both middle turbinates
* Presence of significant concha bullosa, which requires surgical excision
* Presence of non-viable tissue at the implantation site
* Active infection at the implantation site
* Chronic nasal decongestant use (i.e. Afrin, etc)
* Recreational intra-nasal drug use within 12 months of enrollment
* Documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
* Hypersensitivity to any investigational device materials including known or suspected allergy to poly(dioxanone) (PDO) or other bioabsorbable materials
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Spirair, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwest Community Hospital

Arlington Heights, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Tandem Clinical Research

Marrero, Louisiana, United States

Site Status

LSU Health Science Center

Shreveport, Louisiana, United States

Site Status

Houston Methodist ENT Specialists

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Margo Snyder

Role: CONTACT

2069482544

Laura Ino

Role: CONTACT

4083757448

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Henry Mantakul

Role: primary

847-618-4358

Mahendra Shah, MD

Role: primary

312-942-9967

Blaire Willis

Role: primary

5049348424

Teresa Leeth

Role: primary

318-675-7298

Tracy Norwood

Role: backup

Sebastian Guadarrama-Sistos Vazquez, MD

Role: primary

346-356-3640

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT-004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LATERA-OFFICE Study
NCT02964312 COMPLETED NA
NasoNeb Delivery of an Intranasal Steroid
NCT01270256 COMPLETED PHASE4